Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$5.37
+3.1%
$4.71
$3.42
$7.20
$301.87M1.941.53 million shs457,421 shs
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
$5.75
+2.9%
$5.13
$3.79
$14.60
$288.09M-0.921.45 million shs994,920 shs
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
$2.14
-0.5%
$1.89
$0.77
$4.08
$295.93M1.4929,211 shs714,954 shs
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
$0.76
+15.2%
$0.59
$0.20
$0.92
$92.04M2.141.56 million shs12.38 million shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-1.33%-5.27%+7.64%+9.00%-15.83%
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
+1.08%+2.95%+5.87%-29.06%-37.19%
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
+0.47%+2.87%+13.76%-22.66%+52.48%
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
+12.65%+19.74%+1.58%+27.38%-24.73%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.5022 of 5 stars
0.02.00.00.02.60.80.6
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
2.0311 of 5 stars
3.51.00.00.02.51.70.6
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
4.1536 of 5 stars
4.63.00.00.04.15.00.0
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
3.5349 of 5 stars
3.85.00.00.03.41.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
3.67
Strong BuyN/AN/A
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
3.00
Buy$21.00265.22% Upside
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
3.11
Buy$13.13513.32% Upside
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
3.50
Strong Buy$6.00686.37% Upside

Current Analyst Ratings Breakdown

Latest UNCY, CMPX, ACB, and CADL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/27/2025
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$9.00
5/9/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $10.00
4/28/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
4/22/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
4/21/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$24.00 ➝ $24.00
4/21/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
4/21/2025
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$6.00
4/11/2025
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$19.00 ➝ $19.00
4/11/2025
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.50 ➝ $7.50
4/4/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$10.00 ➝ $24.00
4/2/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$320.81M0.94$0.20 per share26.35$8.18 per share0.66
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
$120K2,400.77N/AN/A$0.44 per share13.07
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
$850K348.15N/AN/A$1.17 per share1.83
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
$680K135.35N/AN/A($0.11) per share-6.94
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-$48.62M$0.05107.4212.20N/A0.42%0.59%0.42%6/19/2025 (Estimated)
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
-$37.94M-$1.34N/AN/AN/AN/A-629.29%-173.39%8/12/2025 (Estimated)
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
-$42.49M-$0.41N/AN/AN/AN/A-32.37%-30.67%8/11/2025 (Estimated)
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
-$30.54M-$0.51N/AN/AN/AN/AN/A-29.88%N/A

Latest UNCY, CMPX, ACB, and CADL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/19/2025Q4 2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.11N/AN/AN/A$88.85 millionN/A
5/14/2025Q1 2025
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
-$0.14-$0.05+$0.09-$0.05N/AN/A
5/13/2025Q1 2025
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
-$0.24$0.13+$0.37$0.13N/AN/A
5/8/2025Q1 2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
-$0.12-$0.12N/A-$0.12N/AN/A
3/27/2025Q4 2024
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
-$0.13-$0.26-$0.13-$0.26N/AN/A
3/13/2025Q4 2024
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
-$0.23-$0.40-$0.17-$0.40N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
N/AN/AN/AN/AN/A
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
N/AN/AN/AN/AN/A
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.07
3.30
1.60
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
N/A
1.18
1.18
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
N/A
31.84
31.84
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
N/A
3.61
3.61

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
13.93%
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
68.43%
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
40.42%

Insider Ownership

CompanyInsider Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.01%
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
16.60%
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
29.80%
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
10.71%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,34056.21 million54.85 millionOptionable
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
6050.10 million18.97 millionOptionable
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
20138.28 million98.38 millionNot Optionable
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
9120.63 million78.78 millionNot Optionable

Recent News About These Companies

Q2 Earnings Estimate for UNCY Issued By HC Wainwright
Unicycive Therapeutics initiated with a Buy at Guggenheim
Unicycive presents new patient-level data from Phase 2 study of OLC

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$5.37 +0.16 (+3.07%)
Closing price 04:00 PM Eastern
Extended Trading
$5.38 +0.00 (+0.09%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Candel Therapeutics stock logo

Candel Therapeutics NASDAQ:CADL

$5.75 +0.16 (+2.86%)
Closing price 04:00 PM Eastern
Extended Trading
$5.86 +0.12 (+2.00%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Compass Therapeutics stock logo

Compass Therapeutics NASDAQ:CMPX

$2.14 -0.01 (-0.47%)
Closing price 04:00 PM Eastern
Extended Trading
$2.14 +0.00 (+0.23%)
As of 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Unicycive Therapeutics stock logo

Unicycive Therapeutics NASDAQ:UNCY

$0.76 +0.10 (+15.19%)
Closing price 04:00 PM Eastern
Extended Trading
$0.83 +0.07 (+9.04%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.